News
Pfizer: Xtandi Reduces Risk Of Death By 34% In Men With Metastatic Hormone-Sensitive Prostate Cancer
(RTTNews) - Astellas Pharma Inc. and Pfizer Inc.'s (PFE) Xtandi or enzalutamide improved overall survival in men with metastatic hormone-sensitive prostate cancer, as per a phase 3 ARCHES Study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
